A subsequent goal is to take advantage of the accumulated knowledge of the mechanisms used to confer NF‐κB selectivity to develop therapeutic strategies in order to modulate Bcl‐XL‐mediated drug resistance in CLL. The gene discussed is NFKB1; the disease is B-cell chronic lymphocytic leukemia.